Videos

A 28-day smartwatch study in menopausal women found sleep fragmentation varied from night to night while total sleep time remained stable.

Wearable sleep tracker use was linked to better sleep in patients with insomnia and COMISA, while OSA showed a divergent pattern warranting further study.

Mander highlights sleep as a modifiable dementia risk factor, emphasizing sleep apnea diagnosis and treatment to support brain health.

Emerging data link sleep disorder severity to Alzheimer's biomarker accumulation, with small CPAP studies suggesting partial biomarker reversibility with treatment.

Pauline Maki, PhD, reviews data showing over half of elinzanetant's sleep benefit in postmenopausal women is independent of VMS reduction.

From behavioral therapy to NK3 receptor antagonists, Baker outlines an expanding toolkit for menopausal sleep disturbance.

Baker discusses menopause-related sleep disturbances and why early screening and individualized treatment are critical in primary care.

Xavier Llor, MD, of Yale Medicine, discusses what the updated guidance from the American Cancer Society on colorectal cancer screening mean for primary care.

In the final episode, "Long-Term VMS Management and Key Takeaways for Clinical Practice," the panelists explore the critical importance of viewing menopause management as a long-term, patient-centered endeavor rather than a time-limited intervention.

This episode, titled "Emerging Evidence on NK Receptor Antagonism and Bone Health in VMS," features panelists examining the exploratory endpoints from the OASIS 3 trial and what they may signal about elinzanetant's potential effects beyond VMS relief.

In "Evaluating Newer Non-Hormonal Therapies for VMS," our panel explores the similarities and distinctions between fezolinetant and elinzanetant as NK receptor antagonists, with a focus on how these differences inform clinical decision-making for a patient with inadequate response to MHT.

Menopause brain fog hits careers hard; learn sleep-focused, nonhormonal and hormone options for vasomotor symptoms—guided by patient comfort.

Learn how experts reassess persistent hot flashes after hormone therapy, uncover hidden factors, and combine nonhormonal options for relief.

Payal Kohli, MD, discusses how baxdrostat may fit into hypertension care, including efficacy, patient selection, and monitoring needs.

Tailored follow-ups track lipids, blood pressure, and screenings while coordinating cardiology and endocrinology to manage vasomotor symptoms and reduce cardiovascular risk.

Learn how clinicians debunk hormone therapy myths, set expectations for symptom relief, and tailor menopause care with risk checks and referrals.

Hot flashes and night sweats derail daily life—see how primary care addresses WHI myths and considers safe menopause hormone therapy.

In the final episode, "A Multidisciplinary Approach to VMS and Cardiovascular Health," the panelists explore how effective, team-based care across specialties can optimize health outcomes for women navigating the menopausal transition, and offer closing reflections on the evolving landscape of VMS and cardiovascular risk management.

Learn how clinicians monitor liver safety for hot-flash therapies, compare lab schedules, and build multidisciplinary care for cancer patients.

In this episode, "Practical Strategies for Managing VMS and Cardiovascular Risk in Primary Care," the panelists explore practical approaches to help busy primary care providers incorporate both cardiovascular risk assessment and vasomotor symptom screening into their everyday clinical workflow without sacrificing efficiency or quality of care.

Compare liver-monitoring needs for vasomotor drugs like fezolinetant, and see why multidisciplinary menopause care matters in oncology.

Elinzanetant eases hot flashes fast by targeting KNDy neurons, boosting sleep and helping cancer patients stay on endocrine therapy.

This episode, titled "Elinzanetant for VMS in Breast Cancer Patients: Insights from the OASIS-4 Trial," features panelists discussing the OASIS-4 trial — a study specifically designed to evaluate elinzanetant in women with a history of breast cancer — and its implications for a patient population that has historically had very limited options for VMS management.

Learn how to manage hot flashes and insomnia in breast cancer survivors with NCCN-backed nonhormonal options like elinzanetant.

This episode, titled "Safety and Cardiovascular Considerations of Novel Non-Hormonal VMS Therapies," features panelists conducting a detailed review of the safety data for the two newest FDA-approved non-hormonal treatments for VMS — fezolinetant and elinzanetant — with a particular focus on hepatic monitoring, cardiovascular safety, and practical clinical application.

How EMR reminders streamline cancer screenings—and what patients should know about coverage, copays, and surprise facility fees.

Learn how coaching, EHR reminders, and home kits boost colon cancer screening—plus when stool, colonoscopy, or blood tests fit best.

ACOG 2026: CDC data show many pregnancy-related deaths may be preventable through better care coordination, access, and follow-up.

A breast cancer survivor on anastrozole struggles with relentless hot flashes and insomnia—explore evidence-based, nonhormonal relief options.

In "Novel Non-Hormonal Therapies for VMS: Mechanisms and Clinical Evidence," our panel explores the neurophysiology underlying vasomotor symptoms and the clinical significance of two FDA-approved neurokinin receptor antagonists that represent a meaningful advance in non-hormonal VMS treatment.